Bio­gen pulls the plug on prized IPF drug from $562M+ Stromedix buy­out

One of Bio­gen’s at­tempts to branch out has flopped as the biotech scraps a mid-stage pro­gram for id­io­path­ic pul­monary fi­bro­sis.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters